Jamie joined Genesys Capital in 2002 and became Partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in twelve early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include EBT Medical, Fairhaven Pharmaceuticals and Inversago Pharma. Past board affiliations include Allostera Pharma, gIcare Pharma, Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Jamie also volunteers as a board member for BioteCanada, and an advisor to both the Ontario Genomics Institute (OGI) and the Centre for Commercialization of Regenerative Medicine (CCRM) and as an associate with Creative Destruction Lab (CDL).
Prior to joining Genesys, Jamie worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Jamie completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.